Coronavirus Treatment Acceleration Program (CTAP) Frequently Asked Questions
Consistent with confidentiality restrictions, we report monthly on:
- Approximate number of therapeutic development programs in the planning stages (i.e., active pre-IND programs),
- Approximate number of studies reviewed (i.e., safe-to-proceed INDs),
- Approximate number of studies by treatment type,
- Approximate number of studies by early or late stage,
- Emergency use authorizations and
- NDA and BLA approvals.
This information is available on the CTAP webpage.
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
